Corporadelic

cor-por-ra-del-ic (adj.): manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.

corporadelia
cor-por-ra-de-lia (n.): the world of people, phenomena, or items associated with corporadelic entities.

The term “corporadelic” was initially coined independently and simultaneously by Dr. Katherine MacLean (a former lead researcher and session guide for psilocybin research at Johns Hopkins University School of Medicine) and Brett Greene (co-founder emeritus of Psymposia and founder of psychedelic pharmaceutical company, Adelia Therapeutics) in 2019. Dr. MacLean defined the term as, “manifesting corporations to commodify psychedelic experiences.”

Thea Riofrancos on the Implications of Global Energy Transition and the Impacts of Lithium Extraction

Thea Riofrancos is a political scientist whose research has focused on political conflict related to extraction, energy, and infrastructure in a rapidly warming and politically unstable world. She also serves on the steering committee for Democratic Socialists of America for a Green New Deal.

The Big & Dandy List of Psychedelic-Mining-Extractive-Industry Ties

This list is by no means exhaustive, but it spotlights a number of psychedelic pharmaceutical companies and executives with ties to extractive industry.

Why are so many extractive industry executives speculating on psychedelics?

Extractive industry is highly speculative by nature and firms are risk tolerant—they either “strike gold” or they don’t. When their gambles fail, psychedelic startups can take over their corporate shells to quickly go public with minimal regulatory scrutiny.

Will Extractive Industry Bring Its Disregard for Indigenous People Into The Psychedelic Industry?

A mining firm’s conflict with Argentinian communities illustrates extractive industry’s practices and values, and raises questions about how these corporate approaches will translate into the psychedelic pharmaceutical industry.

As Psychedelics Enter the Mainstream, Mining Companies Look to Dig Up Profits

Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.

Psychedelic Media Should Stop Parroting Corporate Press Releases When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.

When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.

ATAI Life Sciences Company, EmpathBio, Dives Into MDMA Derivatives, Calls MAPS’ Approach “MDMA 1.0” Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

We Need to Talk About MAPS Supporting The Police, The Military, and Violent White Supremacism

For decades, MAPS and other proponents of psychedelic medicalization have justified their emphasis on treating police and soldiers as a political strategy in service to mainstreaming psychedelic drugs. This strategy perpetuates the logic of white supremacy, capitalism, and imperialism.

DARE to Resist White Supremacy and The Police American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Amidst Pandemic, Psychedelic Investor Christan Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Talking Psychedelic Capitalism in a WeWork Ballroom

Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course

The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress

“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Using psychedelic compounds to treat inflammation is interesting, but claiming that, "the primary traditional use," of psychedelics was, "as imperceptible anti-inflammatory agents," just isn’t true.

Could wearable microdosing technology be a thing one day? Personalized perfume patent includes potential for wearable microdosing technology

Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

BBC Duped into Promoting Marketing Scheme for Microdosing Psychedelics A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

What the heck happened to Reality Sandwich?

Reality Sandwich was sold to a group called Delic Corp. Now there's a lawsuit.

This is what psychedelic mainstreaming looks like…in Arizona

As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.


Corporadelic

cor-por-ra-del-ic(adj): manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.

corporadelia
cor-por-ra-de-lia (n.): the world of people, phenomena, or items associated with corporadelic entities.

The term “corporadelic” was initially coined independently and simultaneously by Dr. Katherine MacLean (a former lead researcher and session guide for psilocybin research at Johns Hopkins University School of Medicine) and Brett Greene (co-founder emeritus of Psymposia and founder of psychedelic pharmaceutical company, Adelia Therapeutics) in 2019. Dr. MacLean defined the term as, “manifesting corporations to commodify psychedelic experiences.”

Thea Riofrancos on the Implications of Global Energy Transition and the Impacts of Lithium Extraction

Thea Riofrancos is a political scientist whose research has focused on political conflict related to extraction, energy, and infrastructure in a rapidly warming and politically unstable world. She also serves on the steering committee for Democratic Socialists of America for a Green New Deal.

The Big & Dandy List of Psychedelic-Mining-Extractive-Industry Ties

This list is by no means exhaustive, but it spotlights a number of psychedelic pharmaceutical companies and executives with ties to extractive industry.

Why are so many extractive industry executives speculating on psychedelics?

Extractive industry is highly speculative by nature and firms are risk tolerant—they either “strike gold” or they don’t. When their gambles fail, psychedelic startups can take over their corporate shells to quickly go public with minimal regulatory scrutiny.

Will Extractive Industry Bring Its Disregard for Indigenous People Into The Psychedelic Industry?

A mining firm’s conflict with Argentinian communities illustrates extractive industry’s practices and values, and raises questions about how these corporate approaches will translate into the psychedelic pharmaceutical industry.

As Psychedelics Enter the Mainstream, Mining Companies Look to Dig Up Profits

Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.

Psychedelic Media Should Stop Parroting Corporate Press Releases When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.

When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.

ATAI Life Sciences Company, EmpathBio, Dives Into MDMA Derivatives, Calls MAPS’ Approach “MDMA 1.0” Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

We Need to Talk About MAPS Supporting The Police, The Military, and Violent White Supremacism

For decades, MAPS and other proponents of psychedelic medicalization have justified their emphasis on treating police and soldiers as a political strategy in service to mainstreaming psychedelic drugs. This strategy perpetuates the logic of white supremacy, capitalism, and imperialism.

DARE to Resist White Supremacy and The Police American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Amidst Pandemic, Psychedelic Investor Christan Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Talking Psychedelic Capitalism in a WeWork Ballroom

Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course

The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress

“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Using psychedelic compounds to treat inflammation is interesting, but claiming that, "the primary traditional use," of psychedelics was, "as imperceptible anti-inflammatory agents," just isn’t true.

Could wearable microdosing technology be a thing one day? Personalized perfume patent includes potential for wearable microdosing technology

Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

BBC Duped into Promoting Marketing Scheme for Microdosing Psychedelics A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

What the heck happened to Reality Sandwich?

Reality Sandwich was sold to a group called Delic Corp. Now there's a lawsuit.

This is what psychedelic mainstreaming looks like…in Arizona

As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.